Last reviewed · How we verify
Docetaxel, Liposomal doxorubicine and Cyclophosphamide
Docetaxel, Liposomal doxorubicine and Cyclophosphamide is a Small molecule drug developed by Grupo Oncológico Gallego. It is currently in Phase 2 development.
At a glance
| Generic name | Docetaxel, Liposomal doxorubicine and Cyclophosphamide |
|---|---|
| Sponsor | Grupo Oncológico Gallego |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Neoadjuvant Study Chemotherapy vs Letrozole + Abemaciclib in HR+/HER2- High/Intermediate Risk Breast Cancer Patients (PHASE2)
- Pyrotinib Plus Neoadjuvant Chemotherapy in HR+/HER2-, HER4-High Breast Cancer (PHASE2)
- Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy (PHASE2)
- Adjuvant Systemic Treatment for (ER)-Positive HER2-negative Breast Carcinoma in Women Over 70 According to Genomic Grade (GG): Chemotherapy + Endocrine Treatment Versus Endocrine Treatment (PHASE3)
- SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer (PHASE2)
- Combination Therapy With MYOCET® (Doxorubicin HCL Liposome for Injection) in Participants With HER2-Positive Breast Cancer (PHASE2)
- Neoadjuvant Treatment Pegylated Liposomal Doxorubicin Plus Cyclophosphamide Sequential Docetaxel Plus Trastuzumab and Pertuzumab Versus Docetaxel Plus Carboplatin Combined With Trastuzumab and Pertuzumab in HER-2 Positive Breast Cancer (PHASE3)
- ACHP-THP vs EC-THP as Neoadjuvant Therapy for HER2-positive EBC (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Docetaxel, Liposomal doxorubicine and Cyclophosphamide CI brief — competitive landscape report
- Docetaxel, Liposomal doxorubicine and Cyclophosphamide updates RSS · CI watch RSS
- Grupo Oncológico Gallego portfolio CI
Frequently asked questions about Docetaxel, Liposomal doxorubicine and Cyclophosphamide
What is Docetaxel, Liposomal doxorubicine and Cyclophosphamide?
Docetaxel, Liposomal doxorubicine and Cyclophosphamide is a Small molecule drug developed by Grupo Oncológico Gallego.
Who makes Docetaxel, Liposomal doxorubicine and Cyclophosphamide?
Docetaxel, Liposomal doxorubicine and Cyclophosphamide is developed by Grupo Oncológico Gallego (see full Grupo Oncológico Gallego pipeline at /company/grupo-oncol-gico-gallego).
What development phase is Docetaxel, Liposomal doxorubicine and Cyclophosphamide in?
Docetaxel, Liposomal doxorubicine and Cyclophosphamide is in Phase 2.